Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer clinical trial (NCT04068974). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this combination treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer clinical trial (NCT04068974). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of Camrelizumab and Apatinib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer clinical trial (NCT04068974). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer clinical trial (NCT04068974). Contact the study team or your healthcare provider for specific answers.

Question 5

What will the treatment process look like for me if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer clinical trial (NCT04068974). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any risks or benefits I should be particularly aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer clinical trial (NCT04068974). Contact the study team or your healthcare provider for specific answers.

What this study is about